2004-2007

Company Incorporation

Every requisite for establishing a manufacturing set-up was done from scratch.

Incorporation of the Company. Established the first plant for oral dosage in Baddi HP,Solan, Himachal Pradesh,

Established a dedicated manufacturing site for oral liquid dosage.

2007-2010

Expansion

Incorporated Alydus Biotech to venture into nutraceuticals.

Dedicated a facility for hormones, cosmetics, and dermatology.

2010-2012

Innovations

Innovated bi-layered sustained release tablets for the first time.

Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities.

2012-2015

Market Expansion

Innovated tablet-in-tablet sustained release tablets for the first time. Acquired Apci Biotech manufacturing sites to expand capacity and capabilities. Expanded into the Indian market.

Expanded into the Asian market. Established a research and development laboratory in Baddi, Himachal to venture into the regulated market.

2015-2019

Certifications & Investments

Maxcure Nutravedics Limited received US-NSF certification.

Investment by Ruby Quadria Capital Investment Holdings Pte. Ltd. in Akums, becoming a minority shareholder.

2019-2022

European Accreditation

Started Evitalife Pharma to venture into APIs. Acquisition of a facility at Baddi, Himachal Pradesh by Evitalife Pharma.

Two manufacturing plants accredited with EU GMP, qualifying for exports to European markets. Acquisition of facilities in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.

2022-2023

Acquisitions & Mergers

Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Apci Biotech. Merger of Evitalife Pharma with Apci Biotech.

2023-2024

IPO Listing

Akums achieved a major milestone by going public, reflecting its significant growth and solidifying its leadership in the pharmaceutical industry. The IPO marks a new era for Akums, enabling further expansion and innovation on a global scale.